These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 851762)

  • 1. New strategies for drug monitoring.
    Br Med J; 1977 Apr; 1(6065):861-2. PubMed ID: 851762
    [No Abstract]   [Full Text] [Related]  

  • 2. Monitoring adverse reactions to drugs.
    Dollery CT; Rawlins MD
    Br Med J; 1977 Jan; 1(6053):96-7. PubMed ID: 832028
    [No Abstract]   [Full Text] [Related]  

  • 3. Post-marketing surveillance of adverse reactions to new medicines.
    Wilson AB
    Br Med J; 1977 Oct; 2(6093):1001-3. PubMed ID: 922357
    [No Abstract]   [Full Text] [Related]  

  • 4. Monitoring of drugs after marketing.
    J R Coll Gen Pract; 1983 Jul; 33(252):438-41. PubMed ID: 6887114
    [No Abstract]   [Full Text] [Related]  

  • 5. A prescription for monitoring drugs.
    Marshall E
    Science; 1980 Feb; 207(4433):853-5. PubMed ID: 7355265
    [No Abstract]   [Full Text] [Related]  

  • 6. Why do doctors not report adverse drug reactions?
    Leiper JM; Lawson DH
    Neth J Med; 1985; 28(12):546-50. PubMed ID: 3911083
    [No Abstract]   [Full Text] [Related]  

  • 7. The case for recording events in clinical trials.
    Skegg DC; Doll R
    Br Med J; 1977 Dec; 2(6101):1523-4. PubMed ID: 338116
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Adverse drug reaction reporting systems: the United Kingdom and the United States.
    Scott HD; Thacher A; Rosenbaum SE; Waters WJ; Green M
    R I Med J (1976); 1988 May; 71(5):179-84. PubMed ID: 3387803
    [No Abstract]   [Full Text] [Related]  

  • 9. Are drug companies a little too vigorous?
    Radcliffe M
    Nurs Times; 2004 Jul 13-19; 100(28):156. PubMed ID: 15311541
    [No Abstract]   [Full Text] [Related]  

  • 10. A consideration of the guidelines for investigating potential new drugs in humans in the United Kingdom.
    McGillion FB
    Methods Find Exp Clin Pharmacol; 1979 Apr; 1(1):45-50. PubMed ID: 552581
    [No Abstract]   [Full Text] [Related]  

  • 11. Communicating adverse drug reactions.
    Lancet; 1978 Jan; 1(8056):133. PubMed ID: 87560
    [No Abstract]   [Full Text] [Related]  

  • 12. Compensating the drug victim.
    Lancet; 1978 Jul; 2(8079):26. PubMed ID: 78220
    [No Abstract]   [Full Text] [Related]  

  • 13. Symposium on drug safety. The role of regulatory agencies and industry in assessment of the safety of drugs for use in man. The situation in the United Kingdom.
    Cahal DA
    Can Med Assoc J; 1968 Feb; 98(6):271-5. PubMed ID: 5636096
    [No Abstract]   [Full Text] [Related]  

  • 14. Crying wolf on drug safety.
    Br Med J (Clin Res Ed); 1982 Jan; 284(6311):219-20. PubMed ID: 6799107
    [No Abstract]   [Full Text] [Related]  

  • 15. Secret out-of-court settlements in drug-injury cases.
    Herxheimer A
    Lancet; 1999 Feb; 353(9152):517-8. PubMed ID: 10028977
    [No Abstract]   [Full Text] [Related]  

  • 16. Editorial: The drug makers.
    Med J Aust; 1974 Oct; 2(16):583-4. PubMed ID: 4437418
    [No Abstract]   [Full Text] [Related]  

  • 17. Discussion on control of new drugs.
    Practitioner; 1971 Apr; 206(234):546-50. PubMed ID: 4930721
    [No Abstract]   [Full Text] [Related]  

  • 18. Reasons for disagreement in the standardized assessment of suspected adverse drug reactions.
    Hutchinson TA; Flegel KM; HoPingKong H; Bloom WS; Kramer MS; Trummer EG
    Clin Pharmacol Ther; 1983 Oct; 34(4):421-6. PubMed ID: 6617062
    [No Abstract]   [Full Text] [Related]  

  • 19. First, catch your signal!
    Edwards IR; Lindquist M
    Drug Saf; 2010 Apr; 33(4):257-60. PubMed ID: 20344855
    [No Abstract]   [Full Text] [Related]  

  • 20. Navigating the risk landscape.
    Maynard AD
    Nat Nanotechnol; 2016 Mar; 11(3):211-2. PubMed ID: 26936813
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 8.